Taken together, the findings of the current study and our previous publications strongly suggest efficacy for HGF/c-MET inhibition ± chemotherapy in early, advanced and adjuvant preclinical settings, thus presenting a strong case for clinical trials of this treatment strategy in patients with PC. The gene discussed is MET; the disease is pachyonychia congenita.